<DOC>
	<DOCNO>NCT02544633</DOCNO>
	<brief_summary>MGCD265 orally administer receptor tyrosine kinase inhibitor target MET receptor . This study Phase 2 trial MGCD265 patient locally advance , unresectable metastatic non-small cell lung cancer ( NSCLC ) activate genetic change MET gene ( mutation amplification [ increase number gene copy ] ) . Testing tumor gene change perform tumor tissue blood sample . Patients must previously receive treatment chemotherapy . The number patient enrol depend many enrolled patient experience tumor size reduction . MGCD265 administer orally , twice daily . The study design evaluate whether number patient experience tumor size reduction substantially high would expect available treatment .</brief_summary>
	<brief_title>Phase 2 Study MGCD265 Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations MET</brief_title>
	<detailed_description>If test already perform , study provide test .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Diagnosis nonsmall cell lung cancer Metastatic locally advance disease Prior platinum chemotherapy immunotherapy Test result show genetic change MET tumor gene At least one tumor measure radiographic scan Prior treatment inhibitor MET HGF Prior positive test EGFR mutation ALK gene rearrangement Uncontrolled tumor brain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mirati</keyword>
	<keyword>MGCD265</keyword>
	<keyword>MET</keyword>
	<keyword>NSCLC</keyword>
</DOC>